Negative results of yet another IL-1 inhibitor in the treatment of knee osteoarthritis add to a pool of data indicating that this strategy does not reduce pain or inflammation and is thereby a dead end. Should we therefore shelve further plans to test or use this therapeutic strategy?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Osteoarthritic chondrocytes undergo a glycolysis-related metabolic switch upon exposure to IL-1b or TNF
Cell Communication and Signaling Open Access 14 June 2023
-
Chondroprotective Factors in Osteoarthritis: a Joint Affair
Current Rheumatology Reports Open Access 21 June 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fleischmann, R. M. et al. A phase 2 trial of lutikizumab, an anti-interleukin 1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol. https://doi.org/10.1002/art.40840 (2019).
Chevalier, X. et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61, 344–352 (2009).
Cohen, S. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis. Res. Ther. 13, R125 (2011).
Kapoor, M. et al. Role of pro inflammmatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7, 33–42 (2011).
Bougault, C. et al. Stress-induced cartilage degradation does not depend on the NLRP3 inflammasome in human osteoarthritis and mouse models. Arthritis. Rheum. 64, 3972–3981 (2012).
van Dalen, S. C. et al. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthr. Cartil. 25, 385–396 (2017).
Clements, K. M. et al. Gene deletion of interleukin-1β, interleukin-1β-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial menisectomy. Arthritis Rheum. 48, 3352–3363 (2003).
Richette, P. et al. A high interleukin 1 receptor antagonist/IL-1β ratio occurs naturally in knee osteoarthritis. J. Rheumatol. 35, 1650–1654 (2008).
Kraus, V. B. et al. Effects of intra-articular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthr. Cartil. 20, 271–278 (2012).
Schieker, M. et al. Interleukin-1β inhibition with canakinumab associates with reduced rates of total hip and knee replacement (THR/TKR) and osteoarthritis (OA) symptoms: exploratory results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) [abstract]. Arthritis Rheumatol. 70 (Suppl. 10), 445 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Chevalier, X., Eymard, F. Anti-IL-1 for the treatment of OA: dead or alive?. Nat Rev Rheumatol 15, 191–192 (2019). https://doi.org/10.1038/s41584-019-0185-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0185-y
This article is cited by
-
Osteoarthritic chondrocytes undergo a glycolysis-related metabolic switch upon exposure to IL-1b or TNF
Cell Communication and Signaling (2023)
-
Chondroprotective Factors in Osteoarthritis: a Joint Affair
Current Rheumatology Reports (2019)
